Randomized trial demonstrates MRI-targeted biopsy alone halves overdiagnosis in persons with elevated PSA, suggesting a favorable strategy despite small delays in detecting intermediate-risk tumors.
The avoidance of systematic biopsy in favor of MRI-directed targeted biopsy for screening and early detection in persons with elevated PSA levels reduced the risk of overdiagnosis by half at the cost of delaying detection of intermediate-risk tumors in a small proportion of patients. (Funded by Karin and Christer Johansson's Foundation and others; GÖTEBORG-2 ISRCTN Registry number, ISRCTN94604465.).
No takes yet. Share an insight, caveat, or question.
Hugosson et al. (2022) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: